Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Voting Common Stock, par value $0.0001 per share
-
Shares outstanding
-
52.4M
-
Number of holders
-
65
-
Total 13F shares, excl. options
-
34.3M
-
Shares change
-
+2.39M
-
Total reported value, excl. options
-
$272M
-
Value change
-
+$19.2M
-
Number of buys
-
38
-
Number of sells
-
-13
-
Price
-
$7.94
Significant Holders of TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) as of Q1 2024
70 filings reported holding TCRX - TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share as of Q1 2024.
TScan Therapeutics, Inc. - Voting Common Stock, par value $0.0001 per share (TCRX) has 65 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 34.3M shares
of 52.4M outstanding shares and own 65.46% of the company stock.
Largest 10 shareholders include Lynx1 Capital Management LP (5.22M shares), EcoR1 Capital, LLC (5M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (3.9M shares), BVF INC/IL (2.99M shares), BAKER BROS. ADVISORS LP (2.78M shares), Propel Bio Management, LLC (2.09M shares), VANGUARD GROUP INC (1.81M shares), BlackRock Inc. (1.7M shares), Deer Management Co. LLC (1.25M shares), and Alphabet Inc. (1.08M shares).
This table shows the top 65 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.